-transparent.png){kind=logo}
Low-dose cyclophosphamide treatment of human lymphocyte cultures in concentrations ranging from 0.001 to 0.00001 microgram/ml produced a statistically significant dose response in chromosome breakage and cell death. However, a dose as high as 0.2 micrograms/ml did not produce significant damage in comparably treated whole blood cultures. These results suggest that lymphocytes in culture have the ability to metabolize the nonmutagenic cyclophosphamide parent compound to its more mutagenic metabolite, but that such conversion may be prevented by binding of cyclophosphamide to red blood cells.
Related Publications
L M Sargent, and
B Roloff, and
L F Meisner
October 1974,
Biulleten' eksperimental'noi biologii i meditsiny,
L M Sargent, and
B Roloff, and
L F Meisner
April 2009,
Genetic testing and molecular biomarkers,
L M Sargent, and
B Roloff, and
L F Meisner
January 1999,
Teratogenesis, carcinogenesis, and mutagenesis,
L M Sargent, and
B Roloff, and
L F Meisner
April 2017,
Drug and chemical toxicology,
L M Sargent, and
B Roloff, and
L F Meisner
January 1977,
Acta cytologica,
L M Sargent, and
B Roloff, and
L F Meisner
January 2005,
Drug and chemical toxicology,
L M Sargent, and
B Roloff, and
L F Meisner
January 2011,
Neuropsychobiology,
L M Sargent, and
B Roloff, and
L F Meisner
September 1978,
Mutation research,
L M Sargent, and
B Roloff, and
L F Meisner
June 2010,
Genetic testing and molecular biomarkers,
L M Sargent, and
B Roloff, and
L F Meisner
November 1986,
Investigative radiology,
